Navigation Links
Sequenom Prices Offering of $110 Million of its 5.00% Convertible Senior Notes Due 2017
Date:9/12/2012

SAN DIEGO, Sept. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the pricing of its offering of $110.0 million aggregate principal amount of Convertible Senior Notes due 2017 (the "Convertible Notes") in a private offering.  The sale of the Convertible Notes is expected to close on September 17, 2012, subject to customary closing conditions.  Sequenom also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $20.0 million aggregate principal amount of the Convertible Notes solely to cover over-allotments, if any.  Sequenom intends to use the net proceeds from this offering to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general administrative expenses.

The Convertible Notes will be the senior, unsecured obligations of Sequenom.  They will bear interest at a fixed rate of 5.00% per year, payable semiannually in arrears on April 1 and October 1 of each year, beginning April 1, 2013.  Interest on the Convertible Notes will accrue from September 17, 2012.  The Convertible Notes will mature on October 1, 2017, unless earlier converted, redeemed or repurchased.

The Convertible Notes will be convertible at any time prior to the third trading day immediately preceding the maturity date, at the option of the holders, into shares of Sequenom's common stock.  The conversion rate will initially be 216.0644 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $4.63 per share of common stock), and will be subject to adjustment upon the occurrence of certain events.  In addition, Sequenom will, in certain circumstances
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sequenom Announces Participation At Two Upcoming Investor Conferences
2. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
3. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
4. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
5. Sequenom Announces Participation at the Jefferies Global Healthcare Conference
6. Study In Prenatal Diagnosis Finds Sequenom CMMs MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets
7. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
8. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
9. Sequenom Named to NASDAQ Global Select Market
10. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
11. Sequenom to Host Analyst Day on Monday, November 14, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , , , There is obviously no single , ... amplifications. For example, , depending on the length and sequence ... can differ from each other. Finding the optimal or the , ... and efficient amplification of a specific target. , ...
... Using Eppendorf Mastercycler gradient , , , , ... NPC Laboratory, Institute of Postgraduate Studies and Research, University , of Malaya, Kuala Lumpur, Malaysia , , ... , , ... , , ...
... Plant RNA, Using the Eppendorf Perfect ... , , , Sonja Vorwerk and ... Zchtungsforschung, Carl-von-Linn , Weg 10, 50829 Cologne, Germany , ... , Barbro Patterson, Eppendorf AG, Germany , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 2Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 4Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 2Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 3Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 4Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 6
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "iPhone 5S ... Technology Report" report to their offering. ... Following the acquisition of AuthenTec in July 2012, ... iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... are working with the U.S. Army and neurosurgeons at ... new type of "bioactive" coating for stents used to treat ... blasts. "Stents coated with a bioactive coating might be ... the inside lining of the blood vessel," said Jean Paul ...
... harmful mercury in plants and animals, a new study by ... has compared levels of the chemical in captive dolphins with ... a controlled diet, while the wild mammals dined on marine ... study found lower levels of mercury in the captive animals, ...
... cues in their hunting sequence - capture, handling and consumption ... and which ones they are better off leaving alone or ... their prey, then they assess its size, and finally they ... team from the Smithsonian Tropical Research Institute in Panama is ...
Cached Biology News:Purdue professor to speak before Congress about nanotechnology in brain treatment research 2Purdue professor to speak before Congress about nanotechnology in brain treatment research 3Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 2Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 3What sounds good doesn't always taste good 2
... high gel-strength agarose suitable for a wide ... constant field to Pulsed Field Gel Electrophoresis ... and exclusion limits, Multi ABgarose can effectively ... times. This in turn means reduced band ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Biology Products: